Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Blood (2024) 144 (10): 1083–1092.

https://doi.org/10.1182/blood.2024023962

Published: 2024

Includes: Supplemental data

Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Blood (2024) 143 (16): 1616–1627.

https://doi.org/10.1182/blood.2023021959

Published: 2024

Includes: Supplemental data

Journal Articles

Ibrutinib Added to Standard Conditioning and As Consolidation Therapy Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Primary Analysis of the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201

Charalambos Andreadis, Olivia Bobek, Eric D. Hsi, Timothy S. Fenske, Susan M. Geyer, Patrick J. Stiff, Brian T. Hill, Mitchell Horwitz, Farhad Khimani, Richard F. Little, Shira N. Dinner, Jonathan W. Friedberg, Brad S. Kahl, Miguel-Angel Perales, Steven M. Devine, John P. Leonard, Nancy L. Bartlett

Blood (2023) 142 (Supplement 1): 437.

https://doi.org/10.1182/blood-2023-173742

Published: 2023

Journal Articles

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Blood (2023) 142 (Supplement 1): 2877.

https://doi.org/10.1182/blood-2023-189648

Published: 2023

Journal Articles

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Rory M. Shallis, Ondrej Blaha, Stephanie Halene, Lourdes Mendez, Nikolai A. Podoltsev, Anne Caldwell, Jan Philipp Bewersdorf, Richard F. Little, Richard Piekarz, Mrinal M. Patnaik, Steven D. Gore, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2023-182814

Published: 2023

Journal Articles

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Blood (2023) 142 (Supplement 1): 610.

https://doi.org/10.1182/blood-2023-180107

Published: 2023

Journal Articles

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Blood (2022) 140 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2022-171751

Published: 2022

Journal Articles

A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Jan Philipp Bewersdorf, Rory Michael Shallis, Elad Sharon, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan F. Madanat, Joshua F. Zeidner, Jessica K. Altman, Olatoyosi Odenike, Swaroopa Yerrabothala, Tibor Kovacsovics, Nikolai A. Podoltsev, Stephanie Halene, Richard F. Little, Richard Piekarz, Steven D. Gore, Tae Kon Kim, Amer M. Zeidan

Blood (2022) 140 (Supplement 1): 9084–9086.

https://doi.org/10.1182/blood-2022-158626

Published: 2022

Journal Articles

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Blood (2022) 140 (Supplement 1): 9057–9060.

https://doi.org/10.1182/blood-2022-169307

Published: 2022

Journal Articles

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Anna Moseley, Boris Freidlin, Rory Michael Shallis, Amer M. Zeidan, David A. Sallman, Richard F. Little, Harry P. Erba, Michael L. Leblanc, Megan Othus

Blood (2022) 140 (Supplement 1): 8932–8933.

https://doi.org/10.1182/blood-2022-170376

Published: 2022

Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood (2022) 140 (2): 112–120.

https://doi.org/10.1182/blood.2021014960

Published: 2022

Includes: Supplemental data

Journal Articles

Evaluation of a Rapid Automated Next Generation Sequencing Assay for Precision Medicine in Acute Myeloid Leukemia

Blood (2021) 138 (Supplement 1): 4444.

https://doi.org/10.1182/blood-2021-148926

Published: 2021

Journal Articles

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Jeremy S. Abramson, Amy S. Ruppert, Sharmila Giri, Ann Hudson, Eric D. Hsi, Richard F. Little, Steven D. Gore, Anusha Vallurupalli, Daniel J Landsburg, Brad S. Kahl, Jonathan W. Friedberg, Nancy L. Bartlett, John P. Leonard

Blood (2021) 138 (Supplement 1): 523.

https://doi.org/10.1182/blood-2021-151266

Published: 2021

Journal Articles

S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements

Elizabeth A Brem, Hongli Li, Anne W. Beaven, Paolo F. Caimi, Leandro Cerchietti, Ash A. Alizadeh, Rebecca L. Olin, Norah Lynn Henry, Hildy Dilon, Richard F. Little, Cara Laubach, Michael L. Leblanc, Jonathan W. Friedberg, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 3565.

https://doi.org/10.1182/blood-2021-148193

Published: 2021

Journal Articles

Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)

Amer M. Zeidan, Kevin Roopcharan, Jerry P. Radich, Jan Philipp Bewersdorf, Vijaya R. Bhatt, Elad Sharon, Richard F. Little, Steven D. Gore, Anne Caldwell, Selina M. Luger, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 3613.

https://doi.org/10.1182/blood-2021-145015

Published: 2021

Journal Articles

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Jennifer A. Woyach, Amy S. Ruppert, Gabriela Perez, Allison M Booth, Diane Feldman, Elie G Dib, Aminah Jatoi, Jennifer Le-Rademacher, Nyla A. Heerema, Cecelia Miller, Gerard Lozanski, Richard F. Little, Brian T. Hill, Wei Ding, Richard M. Stone, Sumithra J Mandrekar, John C. Byrd

Blood (2021) 138 (Supplement 1): 3728.

https://doi.org/10.1182/blood-2021-151471

Published: 2021

Journal Articles

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Blood (2021) 138 (Supplement 1): 639.

https://doi.org/10.1182/blood-2021-153146

Published: 2021

Journal Articles

Treatment Outcomes and Prognostic Factors in 40 Patients with Primary Effusion Lymphoma

Krithika Shanmugasundaram, Ramya Ramaswami, Anaida Widell, Ralph Mangusan, Elaine S. Jaffe, Stefania Pittaluga, Hao-Wei Wang, Vickie Ann Marshall, Denise Whitby, Richard F. Little, Mark N. Polizzotto, Thomas S. Uldrick, Robert Yarchoan, Kathryn A. Lurain

Blood (2021) 138 (Supplement 1): 1437.

https://doi.org/10.1182/blood-2021-151409

Published: 2021

Journal Articles

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Blood (2021) 138 (Supplement 1): 1562.

https://doi.org/10.1182/blood-2021-150462

Published: 2021

Journal Articles

Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R

Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani, Andrea Nicole Lucas, Seth M. Steinberg, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Michelle A. Fanale, Ariela Noy, Wyndham H. Wilson, Mark Roschewski

Blood (2021) 138 (Supplement 1): 453.

https://doi.org/10.1182/blood-2021-147451

Published: 2021

NARROW

Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial

Trial in Progress: Venetoclax in Combination with ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN with Excess Blasts (VICTORY MDS/MPN): A Randomized, Phase 2 Trial

Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826

Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Evaluation of a Rapid Automated Next Generation Sequencing Assay for Precision Medicine in Acute Myeloid Leukemia

Randomized Phase II/III Study of DA-EPOCH-R +/- Venetoclax in Previously Untreated Double Hit Lymphoma: Initial Results from Alliance A051701

Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)

A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)

Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy

Treatment Outcomes and Prognostic Factors in 40 Patients with Primary Effusion Lymphoma

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only